ReviewCancer reports (Hoboken, N.J.)2021
The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
Review in Cancer reports (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Hierarchical vision transformers for Epstein-Barr virus status and histological subtype prediction in Hodgkin lymphoma whole-slide images.Journal of pathology informatics · 2026Article
- Predictors of sensitivity to immune therapies in classic Hodgkin lymphoma.Blood neoplasia · 2026Review
- Machine learning model of clinical laboratory data for 30-day mortality of patients with hodgkin's lymphoma in ICU: a retrospective study based on MIMIC-IV database.Clinical and experimental medicine · 2025Article
- Tumor-derived exosomes and their application in cancer treatment.Journal of translational medicine · 2025Review
- Tumor-microenvironment and molecular biology of classic Hodgkin lymphoma in children, adolescents, and young adults.Frontiers in oncology · 2025Review
- Tonsillar cytotoxic CD4 T cells are involved in the control of EBV primary infection in children.Scientific reports · 2024Article
- Review
- The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer.Experimental & molecular medicine · 2022Review
- AuNP Aptasensor for Hodgkin Lymphoma Monitoring.Biosensors · 2022Article
- The Prognostic Value of Eight Immunohistochemical Markers Expressed in the Tumor Microenvironment and on Hodgkin Reed-Sternberg Cells in Pediatric Patients With Classical Hodgkin Lymphoma.Pathology oncology research : POR · 2022Article
- Review
- Industrializing engineered autologous T cells as medicines for solid tumours.Nature reviews. Drug discovery · 2021Review
- The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.Cancer reports (Hoboken, N.J.) · 2021Review
- Genomic Landscape of Hodgkin Lymphoma.Cancers · 2021Review
- Human Adenovirus Serotype 3 Infection Modulates the Biogenesis and Composition of Lung Cell-Derived Extracellular Vesicles.Journal of immunology research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClassical Hodgkin lymphoma (cHL) is a unique lymphoid malignancy with a tumor microenvironment (TME) consisting of a small number of neoplastic-Hodgkin and Reed-Sternberg (H-RS) cells (<1%), surrounded by a large number of nonneoplastic infiltrating immune cells (>90%). The TME of cHL critically depends on immune cells to support tumor growth as H-RS cells cannot survive and proliferate in isolation. RECENT
findingsProgrammed cell death protein 1 (PD-1) ligand expressed on H-RS cells inhibits the clearance of tumor by causing T-cell exhaustion. Nivolumab and pembrolizumab, PD-1 inhibitors, have been proven to be effective in treating adult and pediatric patients with R/R cHL. Tumor-associated macrophages (TAMs) are a central component of TME and are known to cause poor prognosis in adult HL. However, the prognostic impact of CD68+ TAMs in pediatric HL remains ambiguous. EBV modulates the tumor milieu of HL and plays a strategic role in immune escape by enrichment of the TME with T
conclusionThe cHL microenvironment is distinct in adult and pediatric HL. Future studies are required to understand the role of interplay between H-RS cells and EBV-associated microenvironment and their clinical outcome. They may present novel therapeutic targets for the development of antilymphoma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.